Mechanism of anti-FcαRI monoantibody treatment

LIU Chun-bei,QIN Wei-song

DOI: https://doi.org/10.3969/j.issn.1006-298X.2011.06.010

2011-01-01

Abstract:Anti-FcαRI antibody treatment has been reported in recent years to be effective in controlling inflammatory and kidney diseases,such as immune related and nonimmune related renal disease.Inhibitory immunoreceptor tyrosine-based activation motifs(ITAMi) have been found to be involved in the mechanism of treatment other than activating effects,but mechanisms of inhibitory signaling are poorly understood.New evidence of low avidity ligation of the ITAM-associated FcαRI explained how ITAM broadly inhibits heterologous receptors,which involves translocation of receptor and the associated inhibitory Src homology 2(SH2) domain-containing phosphatase-1(SHP-1) to membrane lipid rafts,colocalization of activating receptors with FcαRI and SHP-1 and trafficking to an inhibitory intracellular compartment termed the inhibisome.Thus,ITAM suppressive signals subvert the activating function of rafts to promote incorporation of receptors into supramolecular domains where signaling molecules are deactivated by SHP-1.These results provided new evidence for anti-FcαRI antibody therapy in the treatment of renal disease.